Literature DB >> 23465602

What are the best routes to effectively model human colorectal cancer?

Madeleine Young1, Liliana Ordonez, Alan R Clarke.   

Abstract

Colorectal cancer (CRC) is the third most common cancer in the UK, with over 37,500 people being diagnosed every year. Survival rates for CRC have doubled in the last 30 years and it is now curable if diagnosed early, but still over half of all sufferers do not survive for longer than 5 years after diagnosis. The major complication to treating this disease is that of metastasis, specifically to the liver, which is associated with a 5 year survival of less than 5%. These statistics highlight the importance of the development of earlier detection techniques and more targeted therapeutics. The future of treating this disease therefore lies in increasing understanding of the mutations which cause tumourigenesis, and insight into the development and progression of this complex disease. This can only be achieved through the use of functional models which recapitulate all aspects of the human disease. There is a wide range of models of CRC available to researchers, but all have their own strengths and weaknesses. Here we review how CRC can be modelled and discuss the future of modelling this complex disease, with a particular focus on how genetically engineered mouse models have revolutionised this area of research.
Copyright © 2013 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Year:  2013        PMID: 23465602      PMCID: PMC5528414          DOI: 10.1016/j.molonc.2013.02.006

Source DB:  PubMed          Journal:  Mol Oncol        ISSN: 1574-7891            Impact factor:   6.603


  76 in total

1.  Single Lgr5 stem cells build crypt-villus structures in vitro without a mesenchymal niche.

Authors:  Toshiro Sato; Robert G Vries; Hugo J Snippert; Marc van de Wetering; Nick Barker; Daniel E Stange; Johan H van Es; Arie Abo; Pekka Kujala; Peter J Peters; Hans Clevers
Journal:  Nature       Date:  2009-03-29       Impact factor: 49.962

2.  Intestinal polyposis in mice with a dominant stable mutation of the beta-catenin gene.

Authors:  N Harada; Y Tamai; T Ishikawa; B Sauer; K Takaku; M Oshima; M M Taketo
Journal:  EMBO J       Date:  1999-11-01       Impact factor: 11.598

3.  Foxl1 is a mesenchymal Modifier of Min in carcinogenesis of stomach and colon.

Authors:  Nathalie Perreault; Sara D Sackett; Jonathan P Katz; Emma E Furth; Klaus H Kaestner
Journal:  Genes Dev       Date:  2005-01-13       Impact factor: 11.361

4.  An integrated approach to uncover drivers of cancer.

Authors:  Uri David Akavia; Oren Litvin; Jessica Kim; Felix Sanchez-Garcia; Dylan Kotliar; Helen C Causton; Panisa Pochanard; Eyal Mozes; Levi A Garraway; Dana Pe'er
Journal:  Cell       Date:  2010-12-02       Impact factor: 41.582

5.  Smad3 deficiency promotes tumorigenesis in the distal colon of ApcMin/+ mice.

Authors:  Nicole M Sodir; Xuan Chen; Ryan Park; Andrea E Nickel; Peter S Conti; Rex Moats; James R Bading; Darryl Shibata; Peter W Laird
Journal:  Cancer Res       Date:  2006-09-01       Impact factor: 12.701

6.  A human colon cancer cell capable of initiating tumour growth in immunodeficient mice.

Authors:  Catherine A O'Brien; Aaron Pollett; Steven Gallinger; John E Dick
Journal:  Nature       Date:  2006-11-19       Impact factor: 49.962

7.  Tissue-specific and inducible Cre-mediated recombination in the gut epithelium.

Authors:  Fatima el Marjou; Klaus-Peter Janssen; Benny Hung-Junn Chang; Mei Li; Valérie Hindie; Lawrence Chan; Daniel Louvard; Pierre Chambon; Daniel Metzger; Sylvie Robine
Journal:  Genesis       Date:  2004-07       Impact factor: 2.487

8.  Pathway-specific tumor suppression. Reduction of p27 accelerates gastrointestinal tumorigenesis in Apc mutant mice, but not in Smad3 mutant mice.

Authors:  Jeannette Philipp-Staheli; Kyung-Hoon Kim; Shannon R Payne; Kay E Gurley; Denny Liggitt; Gary Longton; Christopher J Kemp
Journal:  Cancer Cell       Date:  2002-05       Impact factor: 31.743

9.  Epithelial Pten is dispensable for intestinal homeostasis but suppresses adenoma development and progression after Apc mutation.

Authors:  Victoria Marsh; Douglas J Winton; Geraint T Williams; Nicole Dubois; Andreas Trumpp; Owen J Sansom; Alan R Clarke
Journal:  Nat Genet       Date:  2008-11-16       Impact factor: 38.330

10.  Insertional mutagenesis identifies multiple networks of cooperating genes driving intestinal tumorigenesis.

Authors:  H Nikki March; Alistair G Rust; Nicholas A Wright; Jelle ten Hoeve; Jeroen de Ridder; Matthew Eldridge; Louise van der Weyden; Anton Berns; Jules Gadiot; Anthony Uren; Richard Kemp; Mark J Arends; Lodewyk F A Wessels; Douglas J Winton; David J Adams
Journal:  Nat Genet       Date:  2011-11-06       Impact factor: 38.330

View more
  17 in total

1.  Liver-Tumor Hybrid Organoids for Modeling Tumor Growth and Drug Response In Vitro.

Authors:  Aleksander Skardal; Mahesh Devarasetty; Christopher Rodman; Anthony Atala; Shay Soker
Journal:  Ann Biomed Eng       Date:  2015-03-17       Impact factor: 3.934

2.  Evaluating the effectiveness of cancer drug sensitization in vitro and in vivo.

Authors:  Mateusz Rytelewski; Adrian Buensuceso; Hon S Leong; Bonnie J Deroo; Ann F Chambers; James Koropatnick
Journal:  J Vis Exp       Date:  2015-02-06       Impact factor: 1.355

3.  The chemopreventive effect of withaferin A on spontaneous and inflammation-associated colon carcinogenesis models.

Authors:  Balaji Chandrasekaran; Deeksha Pal; Venkatesh Kolluru; Ashish Tyagi; Becca Baby; Nisha R Dahiya; Khafateh Youssef; Houda Alatassi; Murali K Ankem; Arun K Sharma; Chendil Damodaran
Journal:  Carcinogenesis       Date:  2018-12-31       Impact factor: 4.944

4.  A multi-site metastasis-on-a-chip microphysiological system for assessing metastatic preference of cancer cells.

Authors:  Julio Aleman; Aleksander Skardal
Journal:  Biotechnol Bioeng       Date:  2018-12-31       Impact factor: 4.530

5.  Mouse model of proximal colon-specific tumorigenesis driven by microsatellite instability-induced Cre-mediated inactivation of Apc and activation of Kras.

Authors:  Yasuo Kawaguchi; Takao Hinoi; Yasufumi Saito; Tomohiro Adachi; Masashi Miguchi; Hiroaki Niitsu; Tatsunari Sasada; Manabu Shimomura; Hiroyuki Egi; Shiro Oka; Shinji Tanaka; Kazuaki Chayama; Kazuhiro Sentani; Naohide Oue; Wataru Yasui; Hideki Ohdan
Journal:  J Gastroenterol       Date:  2015-09-11       Impact factor: 7.527

6.  Biodegradable fluorescent nanoparticles for endoscopic detection of colorectal carcinogenesis.

Authors:  Stephan Rogalla; Krzysztof Flisikowski; Dimitris Gorpas; Aaron T Mayer; Tatiana Flisikowska; Michael J Mandella; Xiaopeng Ma; Kerriann M Casey; Stephen A Felt; Dieter Saur; Vasilis Ntziachristos; Angelika Schnieke; Christopher H Contag; Sanjiv S Gambhir; Stefan Harmsen
Journal:  Adv Funct Mater       Date:  2019-10-10       Impact factor: 18.808

Review 7.  What are the best routes to effectively model human colorectal cancer?

Authors:  Madeleine Young; Liliana Ordonez; Alan R Clarke
Journal:  Mol Oncol       Date:  2013-02-20       Impact factor: 6.603

Review 8.  Modeling colorectal cancers using multidimensional organoids.

Authors:  Ibrahim M Sayed; Amer Ali Abd El-Hafeez; Priti P Maity; Soumita Das; Pradipta Ghosh
Journal:  Adv Cancer Res       Date:  2021-03-26       Impact factor: 6.242

9.  Dietary fat overcomes the protective activity of thrombospondin-1 signaling in the Apc(Min/+) model of colon cancer.

Authors:  D R Soto-Pantoja; J M Sipes; G Martin-Manso; B Westwood; N L Morris; A Ghosh; N J Emenaker; D D Roberts
Journal:  Oncogenesis       Date:  2016-05-30       Impact factor: 7.485

Review 10.  The utility of Apc-mutant rats in modeling human colon cancer.

Authors:  Amy A Irving; Kazuto Yoshimi; Marcia L Hart; Taybor Parker; Linda Clipson; Madeline R Ford; Takashi Kuramoto; William F Dove; James M Amos-Landgraf
Journal:  Dis Model Mech       Date:  2014-10-02       Impact factor: 5.758

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.